lamivudine / Generic mfg. - LARVOL DELTA

Rapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies. (PubMed, J Chromatogr Sci) - "In addition, the greenness assessment, the holistic overall evaluation and the practicality check using the novel Analytical GREEnness Metric Approach and Software (AGREE) calculator, the RGB-12 model and Blue Applicability Grade Index (BAGI), respectively, were performed. The results demonstrated the environmental friendliness (AGREE), practicality (BAGI) and holistic sustainability profile (RGB-12 model) of the proposed method."

Journal

Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018-2024: a comparison retrospective longitudinal analysis. (PubMed, Lancet Reg Health Afr) - "Long-term virologic outcome data of tenofovir fumarate disoproxil-lamivudine-dolutegravir (TLD) versus tenofovir fumarate disoproxil-lamivudine-efavirenz (TLE) from resource-constrained settings remain limited...No specific funding was received for the analysis. HIV program support was provided by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Combining X‑ray Diffraction, Solid-State NMR, and Computational Chemistry for Structural Insights and Performance Evaluation of GIPAW/GIAO 13C Chemical-Shift Calculations for Lamivudine and Three Pharmaceutical Salts. (PubMed, ACS Omega) - "Two strong, nearly symmetric O···H···O interactions in the hydrogen phthalate salt are reported here for the first time, consistent with the anomalously low pK a2 of ortho-phthalic acid. These results demonstrate that the combined use of periodic GIPAW NMR calculations with QTAIM/NBO analysis constitutes a powerful, generally applicable strategy for the unequivocal structural characterization of pharmaceutical solid forms, with direct implications for the physicochemical quality control of drug substances."

Journal

Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study. (PubMed, JMIR Public Health Surveill) - "Pre-exposure prophylaxis was not associated with overall PDR; however, drug-specific analyses demonstrated significant associations between exposure prophylaxis and pretreatment resistance to emtricitabine (P<.001) and lamivudine (P<.001). HIV-1 genetic diversity in Zhejiang Province remains complex and dynamic, accompanied by an increasing prevalence of PDR. Although exposure prophylaxis was not linked to overall PDR, its association with emtricitabine-specific resistance highlighted the need for strengthened HIV-1 testing prior to prophylaxis initiation and enhanced resistance surveillance, but they require confirmation in future studies."

Journal • Observational data • Human Immunodeficiency Virus • Infectious Disease • CD4

Protective anti-HBs thresholds and risk of De Novo hepatitis B after pediatric liver transplantation using anti-HBc–positive donor grafts (TTS 2026) - "All infected patients were receiving lamivudine prophylaxis at the time of HBsAg positivity and had low anti-HBs levels (0–25 IU/L)... De novo HBV infection may occur despite antiviral prophylaxis when anti-HBs levels are insufficiently maintained. Sustained vaccination-based immunity combined with longitudinal anti-HBs monitoring appears critical for long-term protection in pediatric recipients of anti-HBc IgG–positive donor grafts."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Transplantation

Antiviral Management Patterns and Long-term Outcomes in HBsAg-Positive Kidney Transplant Recipients: A Retrospective Cohort Study (TTS 2026) - "However, comparative data on entecavir (ETV) monotherapy, ETV rescue therapy after prior lamivudine exposure, and self-discontinuation of antiviral therapy are limited... In this real-world cohort of HBsAg-positive KTRs, ETV monotherapy and ETV rescue therapy were associated with comparable long-term graft and patient survival. Self-discontinuation of antiviral therapy was associated with poorer unadjusted outcomes compared with continued ETV-based therapy, although this association was not statistically robust after adjustment. Continued ETV-based management was also associated with a more favorable long-term liver biochemical profile."

Retrospective data • Cardiovascular • Fibrosis • Hepatitis B • Hepatology • Hypertension • Immunology • Infectious Disease • Liver Failure • Transplantation

Thymosin-ɑ1 for people with chronic hepatitis B. (PubMed, Cochrane Database Syst Rev) - "We assessed the certainty of evidence as very low for all outcomes except for serious adverse events (low). Therefore, we are not sure whether thymosin-α1 monotherapy versus placebo or no intervention, or with the same co-interventions, reduces all-cause mortality, serious adverse events, HBV-related mortality, and non-serious adverse events, nor whether it has any effect on quality of life (based on one trial) and histological improvement. The effect of thymosin-ɑ1 on HBV-related morbidity is very uncertain. We observed no statistically significant differences between trials with and without cointerventions. We found no ongoing trials."

Clinical • Journal • Review • Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Oncology • Solid Tumor

A scientometric study on research characteristics of HIV/AIDS involving the oral cavity with an implication for public health. (PubMed, J Dent Sci) - "The trend of drug aspect, e.g., antifungal agent, nystatin, and azole drugs before 2006 has changed to reverse transcriptase inhibitors efavirenz and lamivudine. Herein, we highlight the awareness of early diagnosis, and screening and testing of HIV, e.g., using saliva seems well-suited in dental setting. This study is the first scientometric analysis of HIV-related oral diseases with an implication for public health, underpinning that dentists and stomatologists can play active roles in providing early recognition and timely diagnosis of HIV/AIDS when it involved the oral cavity."

Journal • Candidiasis • Dental Disorders • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Periodontitis • Sarcoma • Solid Tumor

An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance. (PubMed, J Clin Microbiol) - "We demonstrated the assay's feasibility for phenotypic DRT using lamivudine-5'-triphosphate (3TC-TP)-to which the M184V mutation confers high-level resistance-and quantified 3TC-TP inhibition using the difference in cDNA produced between drug and no-drug conditions...Finally, we showed that PERT could detect resistance to existing and emerging RT inhibitors, including tenofovir-diphosphate (TFV-DP), doravirine (DOR), and islatravir (ISL)-TP.IMPORTANCEAlthough antiretroviral therapy can effectively treat and prevent HIV infection, treatment efficacy and global control of the HIV epidemic are threatened by rising rates of HIV drug resistance...Our optimized product-enhanced reverse transcriptase (PERT) assay for simultaneous viral load and phenotypic drug resistance quantification is fast (~2 h), sensitive, and accurate. We can also leverage existing RT-qPCR instruments used for viral load measurement to significantly improve access to HIV drug resistance..."

Journal • Human Immunodeficiency Virus • Infectious Disease

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2026 ➔ Jun 2027 | Trial primary completion date: Jul 2026 ➔ Jun 2027

Enrollment closed • Trial completion date • Trial primary completion date • Inflammation

Lamivudine for Solid Tumors (clinicaltrials.gov) - P1/2 | N=12 | Active, not recruiting | Sponsor: Thomas Marron | Trial completion date: Jul 2026 ➔ Sep 2027

Trial completion date • Oncology • Solid Tumor • PD-L1

LC–MS/MS quantification of tenofovir and lamivudine in low-volume plasma samples: A bioanalytical method for pharmacokinetic evaluation of 3D printed combination formulations | Poster Board #D12 (ACS-Fall 2026) - "This work demonstrates the ability of TQD-based LC–MS/MS methods for high-sensitivity, multi-analyte quantification in small-volume biological samples, supporting advanced drug delivery and translational bioanalysis. Chromatograms of: (A) Plasma, (B) 3TC, (C) TFV, (D) TFV–d6"

PK/PD data

Doravirine/islatravir (Idvynso) for HIV. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis. (PubMed, Int J Mol Sci) - "Lamivudine-associated resistance (rtM204I/V) was the most common RT mutation detected in the overlapping RT/S region. HIV-infected individuals in southern Vietnam face a burden of both CHB and OBI, including a high proportion of seronegative OBI. The presence of seronegative OBI further supports the risk of underdiagnosis when relying only on standard serological markers, and reflects the need for integrated strategies combining highly sensitive serological assays with molecular diagnostics to improve HBV detection among high-risk populations."

Biomarker • Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Longitudinal Hepatic and Metabolic Trajectories Following Dolutegravir Initiation in Antiretroviral Therapy (ART)-Naïve People Living With HIV: A Prospective Cohort Study From South India. (PubMed, Cureus) - "Background Dolutegravir (DTG)-based combination antiretroviral therapy (cART), specifically the tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) regimen, is being widely prescribed for the management of people living with HIV (PLHIV) in India and other low- and middle-income countries. In contrast, body weight and BMI increased progressively throughout follow-up, suggesting that hepatic and metabolic responses to DTG may follow distinct trajectories. Overall, ALT elevations were predominantly mild and self-limited, indicating favorable hepatic tolerability of DTG-based cART in this cohort while highlighting the need for continued metabolic monitoring."

Journal • CNS Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Contemporary Single and Multi-Tablet HIV Treatment Regimens Are Associated With Similar Levels of Viral Suppression. (PubMed, Open Forum Infect Dis) - "In multivariate analysis, lower levels of viral suppression were significantly associated with female sex at birth, younger age, being unstably housed, and use of darunavir-containing MTRs, but not other ART regimens. Viral suppression was lower among persons treated with 2025 US guideline recommended 1st-line MTRs (dolutegravir [DTG] + emtricitabine [FTC]/tenofovir alafenamide [TAF], DTG + FTC/tenofovir disoproxil fumarate [TDF], DTG + lamivudine [3TC]) than bictegravir (BIC)/FTC/TAF, however, this difference was not significant (88.9% vs 91.6%, RRadj = 0.98, 95% CI 0.94-1.01). Viral suppression did not significantly vary between persons on BIC/FTC/TAF and 1st-line MTRs among unstably housed persons (78.8% vs 78.2%, RR = 1.00, 95% CI 0.84-1.19). Differences in viral suppression between contemporary STRs and 1st-line MTRs, if any, are likely small. Factors other than drug efficacy-including cost-should inform decisions to use STRs versus 1st-line MTRs."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease

Efficacy and Safety of Albuvirtide Plus Dolutegravir or Dolutegravir/Lamivudine in Hospitalized People with Advanced AIDS: A Retrospective Real-World Study. (PubMed, AIDS Res Hum Retroviruses) - "No significant differences in efficacy or safety were found between the ABT + DTG and ABT + DTG/3TC regimens. In a real-world setting, ABT-based regimens containing DTG (with or without 3TC) demonstrated high efficacy and excellent safety in hospitalized people with advanced AIDS, supporting its use in this difficult-to-treat population."

Journal • Real-world evidence • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Clinical and virological characteristics of hepatitis B virus genotype E infection: a case series. (PubMed, Infect Dis (Lond)) - "Lamivudine resistance mutations (L180M, M204V) were found in one (12.5%) case, tenofovir resistance-associated mutations (M267L/I) in two (25%) and immune escape mutations in three (37.5%), including T126I, D144E and G145R...In our setting, HBV genotype E infections largely occurred among migrants from endemic regions. Although nucleos(t)ide analogues are effective across genotypes, suboptimal adherence may hinder viral suppression and promote resistance."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Hepatitis B Reactivation After Kidney Transplantation in Hepatitis B Surface Antigen-Positive Recipients. (PubMed, Exp Clin Transplant) - "Although optimal duration of prophylactic antiviral therapy remains unclear, entecavir or tenofovir was the preferred antiviral therapy over lamivudine for hepatitis B virus reactivation prophylaxis. Close monitoring with antiviral prophylaxis is the optimal strategy to prevent hepatitis B virus reactivation during immunosuppressive therapy."

Biomarker • Journal • Retrospective data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Transplantation

Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration (AIDS 2026) - "We assessed CKD risks associated with (1) INSTIs vs non-nucleoside reverse transcriptase inhibitors (NNRTIs) and (2) TAF vs lamivudine (3TC), with both comparators considered kidney neutral...To account for artefactual creatinine increases when starting INSTIs and rilpivirine, baseline was defined as 6 months after starting treatment... After accounting for differences in participant characteristics, there was no increased CKD risk associated with INSTIs or TAF, although confidence intervals were relatively wide."

Cardiovascular • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • CD4

High virological failure in people with major DTG-associated DRTs continuing on standard dose DTG: the Ndovu RCT (AIDS 2026) - "Participants on DTG for at least 6 months, with persistent viraemia of = 200 copies/ml despite enhanced adherence counselling, and = one major DTG-associated drug resistance mutations (DRMs) are randomised 1:1 to continue once daily DTG or to switch to ritonavir boosted darunavir (DRV/r), in combination with tenofovir (abacavir for children <30kg) and lamivudine...Country Kenya Lesotho Mozambique Tanzania 38 (100%) 0 0 0 33 (97.1%) 1 (2.9%) 0 0 Sex Female Male 25(65.8%) 13 (34.2%) 18 (52.9%) 16 (47.1%) Age (years) Median (IQR) =15 years 3-14 years 30.5 (18.0, 42.0) 32 (84.2%) 6 (15.8%) 37.5 (20.0, 44.0) 28 (82.4%) 6 (17.6%) Enrollment Viral Load Category 400-999 1,000-9,999 10,000-99,999 100,000-499,999 =500,000 1 (2.6%) 18 (47.4%) 12 (31.6%) 5 (13.2%) 2 (5.3%) 0 (0.0%) 15 (44.1%) 13 (38.2%) 5 (14.7%) 1 (2.9%) Major resistance mutations DTG associated DRMs G118R +/- (E138K, N155H, R263K) N155H +/- (E92Q) Q148HRK +/- (E138KA, G140A, N155H) R263K PI Major DRMs NRTI..."

Late-breaking abstract • Gene Therapies • Human Immunodeficiency Virus • Infectious Disease

A rapid and inexpensive phenotypic assay for measuring resistance to existing and emerging HIV drugs (AIDS 2026) - "We measured inhibition of HIV-RT activity (viral load ~2500) by the nucleoside RT inhibitor lamivudine-5’-triphosphate (3TC-TP), nucleoside RT translocation inhibitor MK-8591-TP, and non-nucleoside RT inhibitors doravirine and rilpivirine. This PERT assay meets WHO analytical sensitivity requirements for DRT. With its high sensitivity, short duration (~2 hours), compatibility with existing and emerging RT inhibitors, and ability to leverage existing instruments in high- and low-resource settings, this enzymatic assay has the potential to significantly improve access to routine HIV DRT in point-of-care and clinical trial settings."

Human Immunodeficiency Virus • Infectious Disease

Estrogen-Driven Breast Carcinogenesis in a Rat Model is Linked to Retroelement Activation and Inflammation and is Susceptible to Lamivudine Treatment. (PubMed, Breast Cancer (Dove Med Press)) - "Using a rat model, our study demonstrates estrogen dependent ERE expression in pre-invasive ER+FOXA1+ mammary tumor cells and in circulating immune cells, activation of innate immune responses, and the inhibitory effects of 3TC. ERE RNAs and proteins are also highly expressed in human ER+FOXA1+ breast cancers, warranting further investigation into their functions and a potential use of 3TC as a preventive strategy for reducing a risk of cancer progression, especially in woman with ER+FOXA1+ tumors."

Journal • Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Solid Tumor • ER • FOXA1

Prevention of HBV Mother-To-Child Transmission (MTCT) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda. (PubMed, J Viral Hepat) - "HVL mothers received Tenofovir Disoproxil Fumarate plus Lamivudine in the third trimester...Integrating maternal antiviral prophylaxis, targeted BD vaccination, and universal 3D vaccination achieved near-elimination of HBV MTCT in this setting. Nationally scaling this strategy could enable Uganda to meet the WHO target of less than 0.1% infant HBV prevalence before 2030 and serve as a model for other high-burden countries with significant rates of home births."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Low-levels of breakthrough infection and drug resistance among key populations receiving pre-exposure prophylaxis in sub-Saharan Africa: systematic review and meta-analysis (AIDS 2026) - "Interestingly, DRMs reported were M184VI (1/2; specific to Emtricitabine or Lamivudine) and K103N (1/2; specific to Efavirenz and Nevirapine). The low levels of breakthrough infection and HIVDR after PrEP-failure underscore the high benefits of large-scale implementation of PrEP among KP in SSA. Thus, accelerating efforts toward HIV elimination especially in KP requires reinforcing adherence, introducing injectable PrEP, and selecting optimal ART-regimens (guided by HIVDR profiling) following HIV acquisition. PROSPERO registration N°CRD42023463862 Keywords: HIV-1; Key population; Pre-exposure prophylaxis; Drug resistance mutations; Sub-Saharan Africa"

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease